The leading biological adverse event was persistent pain and/or numbness at the implantable pulse generator or lead site, which accounted for 22% of all events.
Dr. Silberstein disclosed that he receives consulting fees/honoraria and research support from St. Jude Medical Neuromodulation Division, which funded the trial.